Showing 4691-4700 of 8832 results for "".
- New Collaboration Seeks to Establish Nocturnal Scratch as a Digital Endpoint for ADhttps://practicaldermatology.com/news/new-collaboration-seeks-to-establish-nocturnal-scratch-as-a-digital-endpoint-for-ad/2460986/Advancing the use of digital endpoints in medical research and care, a new collaboration between
- Gryphon Investors to Acquire Revision Skincarehttps://practicaldermatology.com/news/gryphon-investors-to-acquire-revision-skincare/2460984/Gryphon Investors is set to acquire Revision Skincare and Goodier Cosmetics. The middle-market private equity firm has signed a definitive agreement to acquire the skincare company, with an anticipating closing date this year. Financial terms of the transaction were not disclosed.
- Almirall US Supports The Skin Cancer Foundation’s Mobile Skin Cancer Screening Programhttps://practicaldermatology.com/news/almirall-us-supports-the-skin-cancer-foundations-mobile-skin-cancer-screening-program/2460983/Almirall US is supporting The Skin Cancer Foundation’s mobile skin cancer screening program, Destination Healthy Skin. The Destination Healthy Skin RV travels to cities across the US, where local volunteer dermatologists provide free full-body skin cancer screenings in private exam rooms ab
- FDA Fast Tracks Union Therapeutics' AD Candidatehttps://practicaldermatology.com/news/fda-fast-tracks-union-therapeutics-ad-candidate/2460978/The US Food and Drug Administration (FDA) has granted Fast Track designation to Union Therapeutics’ oral orismilast for the treatment of moderate to severe atopic dermatitis (AD). Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properti
- University of Arkansas Researcher Scores $1.6M NIH Grant for Research on Chronic Skin Woundshttps://practicaldermatology.com/news/puniversity-of-arkansas-researcher-scores-16m-nih-grant-for-research-on-chronic-skin-wounds/2460976/University of Arkansas biomedical engineering professor Kyle Quinn received a four-year, $1.6 million grant from the National Institutes of Health to develop non-invasive, real-time “optical biopsies” of chronic skin wounds. The goal is to provide digital histopathology imag
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 yea
- IFPA Calls for Action Against Psoriasishttps://practicaldermatology.com/news/ifpa-calls-for-action-against-psoriasis/2460971/Today is World Psoriasis Day, and the International Federation of Psoriasis Associations (IFPA) is launching a global petition to demand progress. In 2014, all UN nations unanimously voted to approve the Resolution on Psoriasis (WHA 67.9), committing to improve the l
- European Medicines Agency Set to Review Incyte’s Ruxolitinib Cream in Vitiligohttps://practicaldermatology.com/news/european-medicines-agency-set-to-review-incytes-ruxolitinib-cream-in-vitiligo/2460970/The European Medicines Agency validated the European Marketing Authorization for Incyte’s ruxolitinib cream as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement. The validation of the Marketing Author
- Crown Aesthetics Launches SkinPen Precision Ambassador Programhttps://practicaldermatology.com/news/crown-aesthetics-launches-skinpen-precision-ambassador-program/2460968/Crown Aesthetics announced the launch of their SkinPen Ambassador Program in conjunction with National Microneedling Day. The SkinPen Ambassador Program presents current SkinPen providers with the opportunity to showcase their practice success and to share valuable insights and SkinPen
- Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/castle-creek-biosciences-awarded-fda-orphan-products-development-grant-to-support-phase-3-study-of-fcx-007-investigational-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2460966/The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development awarded Castle Creek Biosciences a $1.825 million research grant to support the Phase 3 development program of the investigational gene therapy FCX-007 for treatment of recessive dystrophic epide